bioMerieux Press ReleasesThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2

52 records returned

bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - November 16, 2009 Category: Biotechnology Source Type: organizations

New A(H1N1) Strain Added to bioMérieux’s Molecular Diagnostic Test NucliSENS EasyQ® Influenza A/BEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A world leader in the field of in vitro diagnostics, bioMérieux has adapted its molecular NucliSENS EasyQ® Influenza A/B test to include the new A(H1N1) strain. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - November 11, 2009 Category: Biotechnology Source Type: organizations

bioMérieux Launches a Molecular Diagnostic MRSA Test on its EasyQ® Automated PlatformEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. bioMérieux, a world leader in the field of in vitro diagnostics, today launched NucliSENS EasyQ® MRSA, a new automated test for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections. NucliSENS EasyQ MRSA is CE marked and bioMérieux will be submitting for 510(k) approval with the U.S. Food and Drug Administration in the first half of 2010. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - November 5, 2009 Category: Biotechnology Source Type: organizations

Alain Pluquet's appointmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A world leader in the field of in vitro diagnostics, bioMérieux has appointed Alain Pluquet to the newly created position of Chief Technology Officer (CTO). (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - November 2, 2009 Category: Biotechnology Source Type: organizations

chromIDTM MRSA Launched in U.S. bioMérieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its ArsenalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chromogenic media provides cost-effective MRSA identification for hospitals and labs. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - October 27, 2009 Category: Biotechnology Source Type: organizations

bioMérieux - Business Review for the nine months ended September 30, 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
2009 Nine-Month Sales up 7.8% at constant exchange rates and scope of consolidation up 11.2% at constant exchange rates, including business development agreements (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - October 19, 2009 Category: Biotechnology Source Type: organizations

2nd World HAI Forum: Experts Discuss Looming Threats to Patient SafetyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Newly evolved enzymes make some bacteria resistant to all common antibiotics Healthcare workers slow to receive flu vaccines Countries not doing enough to combat “superbugs” About 7 million Healthcare-Associated Infections (HAIs) in the U.S. and Europe each year According to a meeting of over 60 infectious disease experts, the global medical community must act on three imminent threats to patients across the world. First threat: common bacteria, such as Escherichia coli (E. coli) are now producing enzymes which make the bacteria capable of de-activating all but the antibiotics that specialists reserve as a last line ...
Source: bioMerieux Press Releases - September 22, 2009 Category: Biotechnology Source Type: organizations

First-Half 2009 ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Growth in sales: 10.3 % - At constant exchange rates, including business development agreements 6.0 % - At constant exchange rates and scope of consolidation Growth in operating results before non-recurring items: 16 % (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - September 6, 2009 Category: Biotechnology Source Type: organizations

bioMérieux - First-Half 2009 Business ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
First-Half 2009 Sales Up 6% at constant exchange rates and scope of consolidation Up 10.3% at constant exchange rates, including business development agreements (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - July 23, 2009 Category: Biotechnology Source Type: organizations

bioMérieux Announces AOAC-RI Certification of its New VIDAS® UP E. coli O157 (Including H7 Strain) Detection KitEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Certification validates high performance test for enhanced food safety. bioMérieux, a world leader in the field of in vitro diagnostics, today announced that an AOAC-RI certification has been granted (No. 060903) to the VIDAS® UP E. coli O157 (Including H7) method for screening beef, selected produce and irrigation water. Food manufacturers in the U.S. and many other countries rely on AOAC-RI certified testing methods to release their products on the market. The new solution is based on recombinant phage protein, the latest technology available for food pathogen screening, which offers unique specificity and sensitivity....
Source: bioMerieux Press Releases - July 8, 2009 Category: Biotechnology Source Type: organizations

bioMérieux Launches VIDAS® EBV, a New Test for the Diagnosis of Infectious MononucleosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics, today launched VIDAS® EBV for the detection of the Epstein-Barr virus (EBV). This virus causes 80% of cases of infectious mononucleosis, which is often known as “the kissing disease” because it is transmitted through saliva. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - June 29, 2009 Category: Biotechnology Source Type: organizations

Communiqué de mise à disposition du document de référence au 31 décembre 2008Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Le Document de référence 2008 de la Société peut être consulté sur le site Internet de l’Autorités des Marchés Financiers (www.amf-france.org) et sur le site Internet de la Société (www.biomerieux.com). (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - June 10, 2009 Category: Biotechnology Source Type: organizations

Communiqué de mise à disposition du rapport financier annuel modifié au 31 décembre 2008Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - June 9, 2009 Category: Biotechnology Source Type: organizations

bioMérieux Launches DiversiLab® Saccharomyces DNA Fingerprinting KitEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Molecular Strain Typing Test to Ensure Consistent Quality of Beer.bioMérieux, a world leader in the field of in vitro diagnostics, has launched the DiversiLab® Saccharomyces DNA Fingerprinting kit, which will accurately and reproducibly identify the strain type of yeast used in the brewing of beer. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - June 7, 2009 Category: Biotechnology Source Type: organizations

Data from Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
- THEROS CancerTYPE ID® predicts cancer origin with 75 percent accuracy in patients whose primary cancer was “unknown” using traditional diagnostics. - bioTheranostics, a bioMérieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that a recent study demonstrated the company’s THEROS CancerTYPE ID® molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose primary cancer was initially “unknown” using traditional diagnostics. Findings were presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting i...
Source: bioMerieux Press Releases - May 31, 2009 Category: Biotechnology Source Type: organizations

bioMérieux Launches Molecular Biology Test, NucliSENS EasyQ® HIV-1 v2.0, for Improved Care of Patients with HIVNew test can be used with the first CE marked Dry Blood Spot sample collection technique for viral load monitoring, bringing testing to patients in remote locationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics, presented the latest addition to its HIV testing offer at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). NucliSENS EasyQ® HIV-1 v2.0 is a test able to detect even very low viral load levels in AIDS patients, offering one of the highest degrees of sensitivity available today. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - May 18, 2009 Category: Biotechnology Source Type: organizations

bioMérieux: Enhancing the Productivity of Microbiology Laboratories with the LeanSigma® MethodEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics, is building upon its Full Microbiology Lab Automation™ (FMLA) concept by offering a new tool to its customers, LeanSigma® - today’s most recognized process and flow improvement methodology. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - May 14, 2009 Category: Biotechnology Source Type: organizations

2009 ESCMID/bioMérieux Research Grant in Clinical MicrobiologyWinner Conducting Research on Major Cause of Healthcare-Associated InfectionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in in vitro diagnostics, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announce the recipient of their 2009 Research Grant, which recognizes excellence and major contributions to progress in the field of clinical microbiology by a young scientist from Eastern Europe. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - May 11, 2009 Category: Biotechnology Source Type: organizations

Communiqué de mise à disposition du rapport financier annuel au 31 décembre 2008Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
La Société annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier annuel au 31 décembre 2008. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - April 29, 2009 Category: Biotechnology Source Type: organizations

First-Quarter 2009 Business Review: Sales Growth in Line with ObjectivesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Up 6.4% - At constant exchange rates and scope of consolidation. Up 10.6% - At constant exchange rates, including business development agreements. bioMérieux, a global leader in the field of in vitro diagnostics, released its quarterly business review through March 31, 2009. As of March 31, 2009, net sales amounted to €286 million, up 6.4% at constant exchange rates and scope of consolidation (on a like-for-like basis) versus the first quarter of 2008. Factoring in sales related to business development agreements, the increase was 10.6% at constant exchange rates. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - April 22, 2009 Category: Biotechnology Source Type: organizations

bioMérieux Unveils its Groundbreaking Culture Media Range for Sterility Control of Aseptic Pharmaceutical PlantsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New range will simplify testing for the pharmaceutical industry. bioMérieux, a world leader in the field of in vitro diagnostics and a leading provider of microbiological solutions for the pharmaceutical industry, launches two innovative culture media for Media Fill Tests (MFT): TSB 3PTM with Animal Peptones and TSB 3PTM with Vegetable Peptones and a color indicator to enhance efficiency and reduce potential errors. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - April 6, 2009 Category: Biotechnology Source Type: organizations

bioMérieux - 2008 Financial ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Board of Directors of bioMérieux, a global leader in the field of in vitro diagnostics, met on Friday, March 13 to approve the consolidated financial statements for the year ended December 31, 2008. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors. Strong sales growth: +9.8%, at constant exchange rates, including business development Improved operating margin before non recurring-items at 16.8% of sales Substantial R&D and manufacturing investments Three strategic acquisitions and expansion of international network (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - March 15, 2009 Category: Biotechnology Source Type: organizations

bioMérieux - 2008 Business ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a global leader in the field of in vitro diagnostics, released its business review for fourth-quarter and full-year 2008. 2008 Sales Up 7.5% at constant exchange rates and scope of consolidation (like-for-like) Up 9.8% at constant exchange rates, including business development agreements (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - January 19, 2009 Category: Biotechnology Source Type: organizations

bioMérieux’s New TEMPO® Solution Delivers Rapid Results on Direct Enumeration of Yeast and Molds to Improve Food SafetyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics, is enhancing its TEMPO® line for food quality with the launch of one of the most rapid automated solutions for direct enumeration of yeast and mold. TEMPO YM delivers final results in half the time versus most other methods, including the ISO reference method (ISO 21527). (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - January 14, 2009 Category: Biotechnology Source Type: organizations

Appointment of Alexandre Mérieux by the bioMérieux Board of DirectorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
At the meeting of the bioMérieux Board of Directors held on December 19, 2008, Alexandre Mérieux was appointed as “Directeur Général Délégué” of the Company. Stéphane Bancel continues to be responsible for all functions in his role as Chief Executive Officer and to chair the bioMérieux Management Committee. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - December 21, 2008 Category: Biotechnology Source Type: organizations

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer SymposiumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Independent studies validate the utility of Theros BCISM for improving risk stratification of early stage breast cancer patients. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - December 13, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Acquires Culture Media Specialist PML Microbiologicals bioMérieux’s recurring sales will be boosted by expanded reagent rangeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics has acquired PML Microbiologicals Inc., a leading provider of culture media and microbiological products in North America for both clinical and industrial applications. This privately held American in vitro diagnostics company has manufacturing and marketing teams based in Portland, Oregon and Toronto, Canada. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - December 7, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Business review for the nine months ended September 30, 2008Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a global leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2008. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - October 27, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Opens a Subsidiary in the Middle East, Continuing its International GrowthEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics, announces the opening of a subsidiary in the United Arab Emirates. A hub for its operations in the Middle East, bioMérieux’s 39th subsidiary will be based in Dubai. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - October 22, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Receives Prestigious Frost & Sullivan 2008 North American Market Leadership Award for Pharmaceutical Microbiology - bioMérieux recognized for outstanding strategic vision in U.S. Rapid Pharmaceutical Manufacturing Microbiology Tests MarketEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce that it is the recipient of the Frost & Sullivan 2008 North American Market Leadership Award for Pharmaceutical Microbiology. bioMérieux received an overall score of 10.13 out of a possible 12.00 points, the highest overall Frost & Sullivan Competitive Metrics Score in the U.S. Rapid Pharmaceutical Manufacturing Microbiology Tests Market. The Market Leadership Award is given to a company that displays overall excellence in the market leadership process, including the identification of market challenges, drivers and restraint...
Source: bioMerieux Press Releases - October 13, 2008 Category: Biotechnology Source Type: organizations

bioMérieux to Develop New Highly-Specific, Non-invasive Test for Prostate Cancer, Reducing Unnecessary BiopsiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - September 24, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Gains Critical Oncology and Theranostics Capabilities with the Acquisition of Molecular Diagnostics Company AviaraDxEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - September 10, 2008 Category: Biotechnology Source Type: organizations

First-Half 2008 Financial Report Sustained sales growth while consolidating profitability - Operating income before non-recurring items up 7.6%Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux (Euronext: BIM), a global leader in the field of in vitro diagnostics, today released its interim financial report for the first six months of 2008. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - September 7, 2008 Category: Biotechnology Source Type: organizations

Steve Harbin's appointmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A world leader in the field of in vitro diagnostics, bioMérieux has appointed Steve Harbin as Corporate Vice President, Quality Management Systems, Health, Safety and Environment and Internal Control, effective July 15, 2008. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - August 31, 2008 Category: Biotechnology Source Type: organizations

bioMérieux - First-Half 2008 ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a global leader in the field of in vitro diagnostics, today released its interim review for the six months ended June 30, 2008. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - July 22, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Increases its Lead in Microbiology with the Acquisition of the Swedish Diagnostics Specialist AB BIODISK. Company’s Etest® will enhance bioMérieux’s high medical-value offer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics has concluded an agreement to acquire the privately held AB BIODISK, a Swedish in vitro diagnostics company with facilities for research and development, manufacturing and marketing located in Stockholm. This is bioMérieux’s fourth acquisition in under two years. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - June 17, 2008 Category: Biotechnology Source Type: organizations

Christian Bréchot Appointed to bioMérieux’s BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Professor Christian Bréchot has been appointed to the Board of Directors of bioMérieux S.A. during its Annual Shareholder’s Meeting, held on June 12th. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - June 12, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Launches Two Innovative Solutions to Detect Food-Borne Pathogens: chromID™ Sakazakii and chromID™ VibrioEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics, is enhancing its line of food safety solutions with the launch of two innovative chromogenic culture media, chromID™ Sakazakii and chromID™ Vibrio. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - June 11, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Unveils Full Microbiology Laboratory Automation Solutions Automation Suite to be showcased at American Society of Microbiology (ASM) in BostonEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in the field of in vitro diagnostics, will unveil a new suite of “Full Microbiology Laboratory Automation” solutions at the 108th General Meeting of the American Society for Microbiology (ASM), held June 1-5 in Boston. bioMérieux believes that full microbiology laboratory automation is imperative to streamlining operations and making more reliable results available faster, particularly in light of the growing threat of healthcare-associated infections. Enhanced automation offsets an increasing lack of specialized personnel, contributing to the control of healthcare expenditures....
Source: bioMerieux Press Releases - May 28, 2008 Category: Biotechnology Source Type: organizations

bioMérieux and FIND to Collaborate on Infectious Disease DiagnosticsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a leader in the field of in vitro diagnostics and FIND (the Foundation for Innovative New Diagnostics), a Swiss non-profit foundation, have signed a Memorandum of Understanding to jointly undertake development projects in the field of infectious disease diagnostics. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - May 14, 2008 Category: Biotechnology Source Type: organizations

bioMérieux - First Quarter 2008 Business ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sales up 6.2% like-for-like. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - April 28, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Bestowed 2007 Frost & Sullivan European Healthcare-Associated Infection Control Technology Leadership AwardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - April 14, 2008 Category: Biotechnology Source Type: organizations

University of Sunderland and bioMérieux Collaborate in New Research Significantly Improving the Identification of Pseudomonas aeruginosa. A Major Cause of Death in Cystic Fibrosis PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .1 (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - April 2, 2008 Category: Biotechnology Source Type: organizations

bioMérieux and Hitachi High-Technologies Corporation Enter into Long-Term Strategic Partnership Focus on Microbiology and Molecular DiagnosticsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics has entered into a long-term strategic partnership with Hitachi High-Technologies Corporation of Japan. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - March 16, 2008 Category: Biotechnology Source Type: organizations

2007 Financial ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
2007: Clear improvement in growthand in operating margin before non-recurring items (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - March 16, 2008 Category: Biotechnology Source Type: organizations

FDA Clears bioMérieux’s VIDAS® NT-proBNP A High Medical Value Test for Diagnosis of Heart FailureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® NT-proBNP, a test that helps the diagnosis of heart failure. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - March 12, 2008 Category: Biotechnology Source Type: organizations

bioMérieux Opens New Subsidiary in SingaporeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announces the opening of a subsidiary in Singapore. This 38th subsidiary is another milestone for the company’s international expansion. It will also advance bioMérieux’s Asian development strategy, following recent announcements of joint ventures in China and Japan. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - March 5, 2008 Category: Biotechnology Source Type: organizations

bioMérieux’s Food Safety Handbook is Now AvailableEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux, a world leader in industrial microbiology control, announces that the first Food Safety Handbook: Microbiological Challenges is now available for food professionals. Published by bioMérieux Editions, the handbook was developed with contributions from 24 internationally renowned experts. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - February 25, 2008 Category: Biotechnology Source Type: organizations

bioMérieux and Wescor Bring a New Gram Staining Instrument for Enhanced Microbiology Laboratory WorkflowEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
bioMérieux (Euronext: BIM) and Wescor, an ELITech Group Company have signed an agreement by which bioMérieux will become Wescor’s exclusive worldwide partner for marketing two customized slide stainer instruments for Gram and tuberculosis bacillus under the bioMérieux brand. (Source: bioMerieux Press Releases)
Source: bioMerieux Press Releases - February 13, 2008 Category: Biotechnology Source Type: organizations